CClinicalTrials.gg
CompletedNCT03803072Updated Mar 16, 2023

A Novel Diet Approach to Combat Gestational Diabetes

An interventional study of time restricted eating (TRE) in Diabetes, Gestational, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

There is an urgent need to implement novel diet approaches to combat the increasing rates of gestational diabetes mellitus (GDM). The primary aim of this study is to establish the feasibility of time-restricted eating in pregnancy, to prepare for future larger controlled trials in this research project to determine the efficacy of time-restricted eating in women at risk of GDM. Expectations:

  1. Women who have an increased risk of GDM will be able to adhere to time reduced eating during pregnancy.
  2. Time reduced eating will improve short-term glycemic control in pregnancy.
02

Conditions studied

  • Diabetes, Gestational

Keywords

  • Exercise therapy
  • Diet
  • Prevention and control
03

In context

Diabetes, Gestational

842 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

This study's enrollment of 32 is below the median of 110 across 550 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 487 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • carrying one singleton live foetus
  • in pregnancy week 12-30
  • having at least one risk factor for gestational diabetes mellitus (GDM) according to Norwegian guidelines for GDM screening: pre-pregnancy BMI > 25 kg/m2, GDM in previous pregnancy, primiparae aged > 25 years, first degree relative with diabetes mellitus, Asian or African ethnicity, previous delivery of new-born > 4.5 kg
  • understand written and spoken Norwegian language

Exclusion criteria

Exclusion Criteria:

  • habitual eating window \< 12 hours
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Time restricted eating (TRE)

    prolonging the duration of fasting between the last evening meal and the first meal of the next day

    Behavioral: time restricted eating (TRE)

  • No intervention
    control

    Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy

Interventions

  • Behavioraltime restricted eating (TRE)

    Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.

06

What researchers measure

Primary outcomes

  1. Change in average time-window for energy intake

    Average daily time-window for energy intake will be registered through log books.

    Time frame: Change between baseline (pre-intervention) time-window for energy intake to average time-window for energy intake during the 5-week intervention period

  2. Weekly adherence rates for time restricted eating (TRE)

    The number of days per week that the participants are able to adhere to TRE, as calculated as weekly average of days with a time-window ≤ 10 hours

    Time frame: Weekly measures throughout the 5 week period of TRE intervention

Secondary outcomes

  1. Perceived barriers to the protocol assessed with an unstructured interview

    Participants will be asked about which barriers they perceived as challenging regarding keeping to a TRE schedule and if they have strategies to overcome these barriers.

    Time frame: Weekly phone calls to participants in TRE group during the 5-week intervention period and after 6 weeks

  2. Subjective appetite sensations assessed by Visual Analogue Scales

    Paper line scales 100 mm on scales for Hunger ("How hungry are you": From "Not at all" = 0 on the scale to "Extremely. As hungry as I have ever felt" =100 on the scale, Fullness (From "Not at all" = 0 on the scale to "Extremely. As full as I have ever felt" = 100 on the scale, Satiety ("How satiated are you" From "Not at all" =0 on the scale to "Extremely" =100 on the scale, Desire to eat ("How strong is your desire to eat" From "Very weak. Extremely low" = 0 on the scale to "Very strong. Extremely high" = 100 on the scale and Prospective consumption (quantity) ("How much do you think you could (or would want to) eat right now?" From "Nothing at all" = 0 on the scale to "A very large amount" = 100 on the scale. Scales will be filled in in the morning, before dinner and at bedtime.

    Time frame: Once weekly throughout 6 weeks, on a weekday.

  3. Change between baseline and post-intervention in fasting glucose

    Post-intervention fasting glucose minus pre-intervention fasting glucose

    Time frame: 6 weeks

  4. Change between baseline and post-intervention in postprandial glucose

    Blood glucose levels 120 minutes after ingestion of 75 g glucose (oral glucose tolerance test)

    Time frame: 6 weeks

  5. Change between baseline and post-intervention in fasting insulin

    Circulating insulin levels

    Time frame: 6 weeks

  6. Change between baseline and post-intervention in postprandial insulin

    Circulating insulin levels 120 minutes after ingestion of 75 g glucose.

    Time frame: 6 weeks

  7. Change between baseline and post-intervention blood pressure

    Diastolic and systolic blood pressure

    Time frame: 6 weeks

  8. Change between baseline and post-intervention body mass

    Body mass in kg.

    Time frame: 6 weeks

  9. Change in total cholesterol

    Total cholesterol measured in blood

    Time frame: 6 weeks

  10. Change in triglycerides

    Triglycerides measured in blood

    Time frame: 6 weeks

  11. Change in HDL cholesterol

    HDL cholesterol measured in blood

    Time frame: 6 weeks

  12. Change in LDL cholesterol

    LDL cholesterol measured in blood

    Time frame: 6 weeks

  13. Change in HbA1c

    HbA1c measured in blood

    Time frame: 6 weeks

  14. Continuous glucose monitoring

    Interstitial glucose measurements

    Time frame: 6 weeks

  15. Change between baseline and post-intervention fat mass

    Fat mass in kg and percent of body mass

    Time frame: 6 weeks

  16. Change between baseline and post-intervention muscle mass

    Muscle mass in kg

    Time frame: 6 weeks

  17. Change between baseline and post-intervention visceral fat area

    Visceral fat area in squared cm.

    Time frame: 6 weeks

07

Study locations

1 site
  • St Olavs Hospital
    Trondheim, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03803072
Lead sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Jan 18, 2019
Primary completion
Mar 13, 2023
Completion
Mar 15, 2023
Last update
Mar 16, 2023

Study contacts

Øystein Risa, phd
study director · Department of circulation and medical imaging, NTNU

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion